<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40992799</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1876-7605</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>18</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>JACC. Cardiovascular interventions</Title><ISOAbbreviation>JACC Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Validation of Intravascular Ultrasound-Defined Optimal Stent Expansion Criteria for Favorable 1-Year Clinical Outcomes.</ArticleTitle><Pagination><StartPage>2197</StartPage><EndPage>2205</EndPage><MedlinePgn>2197-2205</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcin.2025.07.024</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1936-8798(25)01932-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Robust evidence on optimal stent expansion using intravascular ultrasound (IVUS) is still lacking.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to validate the impact of different criteria for IVUS-defined optimal stent expansion on 1-year clinical outcomes after percutaneous coronary intervention (PCI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Individual patient data from 3 randomized trials were aggregated for this analysis. Patients (n = 6,290) were classified into 3 groups: optimized PCI by IVUS, nonoptimized PCI by IVUS, and angiography-guided PCI. The primary endpoint was target vessel failure (TVF) at 1 year, a composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Angiography-guided PCI was performed in 3,208 patients. Optimal stent expansion was evaluated in 3,082 patients with IVUS-guided PCI. For the absolute criterion of minimal stent area (MSA) &gt;5.5 mm<sup>2</sup> indicating optimal stent expansion, the optimized PCI group had a lower incidence of TVF (1.45% vs 3.86% vs 5.07%) compared with the nonoptimized PCI group (adjusted HR: 0.45; 95% CI: 0.26-0.75; P = 0.002) and the angiography-guided PCI group (adjusted HR: 0.35; 95% CI: 0.22-0.54; P &lt; 0.001). Relative criteria did not show a significantly different TVF incidence between the optimized and nonoptimized PCI groups. In particular, the absolute criterion of MSA &gt;5.5 mm<sup>2</sup> was associated with a significant reduction of the composite of cardiac death or target vessel myocardial infarction (0.54% in the optimized PCI group vs 1.59% in the nonoptimized PCI group; adjusted HR: 0.39; 95% CI: 0.17-0.91; P = 0.028).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Post-PCI stent expansion meeting an absolute criterion of MSA &gt;5.5 mm<sup>2</sup> was associated with the most favorable clinical outcomes. (Effect of Intravascular Ultrasound in Patients Receiving Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: An Individual Patient Data Meta-Analysis of IVUS-XPL, ULTIMATE and IVUS-ACS Randomized Trials; CRD42024559794).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang-Hyup</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yong-Joon</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kan</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seung-Jun</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Sung-Jin</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Chul-Min</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jung-Sun</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Byeong-Keuk</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Young-Guk</ForeName><Initials>YG</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Donghoon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Yangsoo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiology, CHA University College of Medicine, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Gregg W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintz</LastName><ForeName>Gary S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Foundation, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shao-Liang</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. Electronic address: chmengx@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Myeong-Ki</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Electronic address: mkhong61@yuhs.ac.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Cardiovasc Interv</MedlineTA><NlmUniqueID>101467004</NlmUniqueID><ISSNLinking>1936-8798</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018084" MajorTopicYN="Y">Ultrasonography, Interventional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015607" MajorTopicYN="Y">Stents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">angiography</Keyword><Keyword MajorTopicYN="N">stent(s)</Keyword><Keyword MajorTopicYN="N">ultrasound</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures Dr M.-K. Hong has received speaker fees from Medtronic and Edward Lifesciences; and has received institutional research grants from Sam Jin Pharmaceutical and Chong Kun Dang Pharmaceutical. Dr Chen has received speaker fees from MicroPort, Pulnovo Medical, Boston Scientific, Medtronic, Sanofi, and BioMed; and has received grants from the National Scientific Foundation of China. Dr Mintz has received speaker fees from Boston Scientific, Abbott Laboratories, and SpectraWAVE. Dr Stone has received speaker honoraria from Pulnovo Medical, Medtronic, Amgen, Boehringer Ingelheim, and Abiomed; has served as a consultant to CorFlow, Cardiomech, Robocath, Daiichi-Sankyo, Ablative Solutions, Vectorious, Miracor, Apollo Therapeutics, Elucid Bio, Abbott Laboratories, Cardiac Success, Occlutech, Millennia Biopharma, Remote Cardiac Enablement, Valfix, Zoll, HeartFlow, Shockwave Medical, Impulse Dynamics, Adona Medical, Oxitope, HighLife, Elixir, and Aria; and has equity or options in Cardiac Success, Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWAVE, Orchestra Biomed, Aria, Valfix, and Xenter. Dr Stone&#x2019;s employer, Mount Sinai Hospital, has received research grants from Shockwave Medical, Biosense Webster, Abbott Laboratories, Abiomed, Bioventrix, Cardiovascular Systems, Phillips, Vascular Dynamics, Pulnovo Medical, V-Wave and the Patient-Centered Outcomes Research Institute (via Weill Cornell Medical Center). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>20</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40992799</ArticleId><ArticleId IdType="doi">10.1016/j.jcin.2025.07.024</ArticleId><ArticleId IdType="pii">S1936-8798(25)01932-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>